A study to test different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with KRAS mutation.
1472-0001
Phase 1 other active
Quick answer
A study to test different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with KRAS mutation. for solid tumour harbouring G12C mutation is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- solid tumour harbouring G12C mutation
- Phase
- Phase 1
- Modality
- other
- Status
- active